DexCom Inc announced on Wednesday that it will present new clinical and real-world evidence demonstrating the benefits of its glucose biosensing technology at the Advanced Technologies and Treatments for Diabetes Conference 2026 taking place in Barcelona from 11 March to 14 March 2026.

Data from a multi-centre primary care registry showed that one year of using the Dexcom G7 continuous glucose monitoring (CGM) system improved A1C levels and supported weight management in people with Type 2 diabetes who are not treated with insulin. The findings reinforce calls to expand CGM access beyond insulin-treated patients.

Additional research presented at the conference indicated that initiating Dexcom CGM was associated with reduced hospitalisations and emergency room visits related to diabetic ketoacidosis in both children and adults with Type 1 diabetes. A separate feasibility study also showed that Dexcom Smart Basal was safe and effective for people with Type 2 diabetes beginning or optimising basal insulin therapy.

During a company symposium on 12 March 2026, Dexcom will outline its product roadmap, including updates to the Dexcom G7 platform, Dexcom G7 15 Day, Dexcom ONE+, Stelo and the Clarity data platform, alongside an introduction to a next-generation sensor.

The company will also present a consensus-based CGM competency framework aimed at helping healthcare professionals deliver consistent CGM training and support. The framework underpins the Dexcom Academy education platform, which is currently available in Belgium, Germany, Saudi Arabia, the Netherlands and Spain, with further launches planned in Italy, Poland, Turkey and Sweden during 2026.

Dexcom said the conference presentations build on the recent retail launch of the Dexcom G7 15 Day system in the US and reflect its continued focus on product innovation, evidence generation and professional education in diabetes care.